Last edition
News about "Tocilizumab Biosimilar"
Celltrion Launches Tocilizumab Biosimilar AVTOZMA IV in the US Market
AVTOZMA is Celltrion's fifth immunology biologic and seventh biosimilar approved by the US FDA. It will be available in the same presentations as its reference product, Actemra (tocilizumab).
Tocilizumab Biosimilar | 03/10/2025 | By Dineshwori | 237
Mochida Seeks Japan's Approval for Tocilizumab Biosimilar in Partnership with AYUMI
This application is based on the results of a Phase I clinical study conducted in Japan with 110 healthy adults and a Phase III clinical study conducted in Japan with 368 patients with rheumatoid arthritis.
Tocilizumab Biosimilar | 28/03/2025 | By Abha | 483
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy